Heartland ISP Leverages OcNOS to Support Scalable, Cost-Effective Broadband Infrastructure Across 11 States
Santa Clara, CA – October 9, 2025 – IP Infusion, a global leader in open networking software solutions, today announced that Nextlink Internet, a fast-growing Internet Service Provider serving the rural heartland of America, has deployed IP Infusion's OcNOS Service Provider and Data Center software running on Edgecore hardware in production across key areas of its middle mile and data center infrastructure.
Headquartered in Texas and operating across 11 states, Nextlink delivers high-speed fixed wireless and fiber-optic internet services to nearly 100,000 customers. The company plays a vital role in bringing connectivity to underserved communities across the Midwest, Great Plains, and beyond. As part of its ongoing commitment to scalable, cost-effective broadband expansion, Nextlink has deployed OcNOS to enhance transport aggregation, site router switching, and core data center operations.
OcNOS enables advanced traffic engineering capabilities, including Segment Routing (SR), MPLS, and ISIS, and integrates with Edgecore's open hardware platforms supporting 100G and 400G interfaces. Seamless integration with Nextlink's NETCONF/YANG-based network automation tools further enhances operational efficiency and deployment flexibility.
"IP Infusion's OcNOS software, paired with Edgecore hardware, is now part of our production environment supporting middle-mile and data center transport," said Cameron Kilton, Chief Technology Officer at Nextlink Internet. "In these targeted use cases, the platform's flexibility, support for open standards, and cost structure align well with our goals to expand broadband access throughout the Heartland while maintaining operational agility and performance."
"Nextlink Internet's rapid growth and commitment to delivering unlimited, high-quality internet align perfectly with our mission to provide scalable, open networking solutions," said Kiyo Oishi, CEO for IP Infusion. OcNOS empowers Nextlink to optimize its network performance while significantly reducing costs, and we're thrilled to support its expansion across 11 states."
The deployment is part of Nextlink's broader network strategy to combine traditional and disaggregated architectures in ways that best serve rural communities with high-quality, unlimited internet.
IP Infusion 소개
IP Infusion develops open network software solutions for carriers, service providers, and data centers. With hundreds of customers and thousands of deployments, IP Infusion leads the market in Network Operating Systems. Its flagship platform, OcNOS®, empowers network operators to disaggregate their networks, streamline operations, and reduce total cost of ownership (TCO). Headquartered in Santa Clara, Calif., IP Infusion is a wholly owned subsidiary of ACCESS CO., LTD. For more information, visit www.ipinfusion.com/.
About Nextlink Internet
Nextlink Internet is a leading ISP serving nearly 100,000 customers across 11 states in the rural Heartland. Headquartered in Texas, the company provides high-speed fixed wireless and fiber-optic internet and voice services to residential, commercial, education, and public sector markets. With a mission to close the digital divide, Nextlink is committed to delivering affordable, reliable, and truly unlimited internet to underserved communities. For more information, visit www.nextlinkinternet.com.
-end-
미디어 문의
Katherine Verducci, 1903 PR
kverducci@1903pr.com
408.429.5779
IP Infusion 소개
IP Infusion은 오픈 네트워킹 소프트웨어의 선도적 공급업체로, 서비스 사업자, 데이터센터, AI 패브릭 네트워크를 위한 통신사업자급 네트워크 운영체제 OcNOS를 제공합니다. 1999년부터 쌓아 온 네트워킹 전문성과 전 세계 600개 이상의 사업자를 바탕으로, IP Infusion은 Edgecore Networks, UfiSpace, Celestica 등 파트너의 검증된 개방형 하드웨어에서 개방적이고 멀티벤더이며 비용 효율적이고 유연한 네트워크 인프라를 구현합니다. IP Infusion은 ACCESS CO., LTD.(도쿄증권거래소: 4813)의 전액 출자 자회사입니다.
미디어 문의
For press inquiries, analyst briefings, or media materials, please 팀에 문의 or email pr@ipinfusion.com.
미래예측 진술
본 보도자료에는 IP Infusion의 제품, 기술 및 계획에 관한 미래예측 진술이 포함될 수 있습니다. 미래예측 진술은 공개일 현재 이용 가능한 정보에 기초하며 위험과 불확실성을 수반합니다. 실제 결과는 다를 수 있습니다. 제품 계획, 기능, 출시 시기 및 제공 여부는 예고 없이 변경될 수 있으며 약정, 약속 또는 법적 의무를 구성하지 않습니다. IP Infusion은 미래예측 진술을 갱신할 의무를 지지 않습니다.